CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF440 (ImmuneEditome ID:126070)

1. Gene summary of enriched editing regions for ZNF440

check button Gene summary
Gene informationGene symbol

ZNF440

Gene ID

126070

GeneSynonyms-
GeneCytomap

19p13.2

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 440
GeneModificationdate20230518
UniprotIDQ8IYI8;C9J3D9;C9JG89;C9JV94;K7EJ55
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:11814977-11819628:+ENST00000587795.1ENSG00000171295.11ZNF440ncRNA_exonicLTR24C,LTR10B1,AluY,MER57E3,MER4D,MER49,AluSq2,AluSg,AluSz,(CA)n,MER41D,AluJr,AluSx,AluJochr19:11814977-11819628:+.alignment
chr19:11822622-11825135:+ENST00000304060.8ENSG00000171295.11ZNF440intronicL1M5,AluSx4,AluSq2,MLT1A,AluJo,FLAM_C,AluSp,L1MC2,L1ME3Bchr19:11822622-11825135:+.alignment
chr19:11822622-11825135:+ENST00000427505.4ENSG00000171295.11ZNF440intronicL1M5,AluSx4,AluSq2,MLT1A,AluJo,FLAM_C,AluSp,L1MC2,L1ME3Bchr19:11822622-11825135:+.alignment
chr19:11822622-11825135:+ENST00000457526.1ENSG00000171295.11ZNF440intronicL1M5,AluSx4,AluSq2,MLT1A,AluJo,FLAM_C,AluSp,L1MC2,L1ME3Bchr19:11822622-11825135:+.alignment
chr19:11822622-11825135:+ENST00000588954.4ENSG00000171295.11ZNF440intronicL1M5,AluSx4,AluSq2,MLT1A,AluJo,FLAM_C,AluSp,L1MC2,L1ME3Bchr19:11822622-11825135:+.alignment
chr19:11828388-11830024:+ENST00000414255.1ENSG00000171295.11ZNF440UTR5AluSz,MER68B,AluSc8,LTR60,L1MB2,AluSpchr19:11828388-11830024:+.alignment
chr19:11834104-11835237:+ENST00000304060.8ENSG00000171295.11ZNF440UTR3AluY,MER90a,AluSx3,(TTGGCC)n,AluSq2chr19:11834104-11835237:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF440


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:11834104-11835237:+COADEER3.1576e-12image
ENSG00000171295.11,ZNF440COADEAG2.7666e-12image
chr19:11834104-11835237:+HNSCEER2.9587e-03image
ENSG00000171295.11,ZNF440HNSCEAG1.6500e-03image
chr19:11834104-11835237:+KICHEER5.2057e-03image
ENSG00000171295.11,ZNF440KICHEAG5.2057e-03image
chr19:11834104-11835237:+STADEER2.3267e-02image
ENSG00000171295.11,ZNF440STADEAG3.0959e-02image
chr19:11834104-11835237:+THCAEER3.1109e-04image
ENSG00000171295.11,ZNF440THCAEAG2.7415e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:11834104-11835237:+BLCAPathEER1.4515e-029.5739e-030.1310image
ENSG00000171295.11,ZNF440BLCAPathEAG1.1438e-021.5394e-020.1225image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:11834104-11835237:+READEER3.7366e-022.7198e-031.4759e+04image
ENSG00000171295.11,ZNF440READEAG3.7366e-022.2486e-031.9437e+04image
ENSG00000171295.11,ZNF440UCECEAG4.2124e-023.7234e-021.7948e+01image

Top

3. Enriched editing regions and immune related genes for ZNF440


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:11834104-11835237:+BLCAEERENSG00000171295,ZNF440-0.50406.1529e-239.2332e-22-0.4594imageNBUD13;CPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;SF3B4;TARDBP;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_COMPLEMENT
chr19:11834104-11835237:+BLCAEERENSG00000156535,CD1090.49722.4269e-221.2908e-180.4259imageNEIF4A3;ELAVL1;FBL;PRPF8;SF3B4;TARDBP;U2AF2;UPF1CD109T_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:11834104-11835237:+BLCAEERENSG00000147065,MSN0.50323.8067e-227.8885e-240.4796imageNCPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;TARDBP;U2AF2;UPF1MSNMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr19:11834104-11835237:+BLCAEERENSG00000019102,VSIG2-0.49573.1582e-215.6267e-18-0.4186imageNEIF4A3;FBL;PRPF8;SF3B4VSIG2T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr19:11834104-11835237:+BLCAEERENSG00000116701,NCF20.48708.7667e-211.0074e-200.4488imageNEIF4A3;ELAVL1;UPF1NCF2T_cells_CD4_memory_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr19:11834104-11835237:+BLCAEERENSG00000114450,GNB40.48232.1841e-206.3694e-200.4403imageNCPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;TARDBP;U2AF2;UPF1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr19:11834104-11835237:+BLCAEERENSG00000134470,IL15RA0.47881.9122e-191.6241e-160.4012imageNCPSF6;EIF4A3;ELAVL1;FBL;KHDRBS1;PRPF8;TARDBP;U2AF2;UPF1IL15RAT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:11834104-11835237:+BLCAEERENSG00000005893,LAMP20.47662.2697e-198.3925e-180.4166imageNBUD13;CPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;SF3B4;TARDBP;U2AF2;UPF1LAMP2T_cells_regulatory_(Tregs)GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr19:11834104-11835237:+BLCAEERENSG00000188641,DPYD0.47722.6979e-198.2362e-170.4048imageNBUD13;EIF4A3;ELAVL1;FBL;PRPF8;TARDBP;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:11834104-11835237:+BLCAEERENSG00000164111,ANXA50.46375.1135e-194.4590e-310.5414imageNBUD13;CPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;SF3B4;TARDBP;U2AF2;UPF1ANXA5T_cells_CD4_memory_activatedGSVA_HALLMARK_COMPLEMENT

More results



Top

4. Enriched editing regions and immune related splicing for ZNF440


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000171295.11,ZNF440
BLCAEAGIRENSG00000089159.11chr12120215102:120215417:120215559:120215655-0.29972.6467e-093.1629e-14-0.4310imageNADAR;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184PXNMacrophages_M1GSVA_HALLMARK_MTORC1_SIGNALING
chr19:11834104-11835237:+
BLCAEERIRENSG00000089159.11chr12120215102:120215417:120215559:120215655-0.32187.3921e-111.9643e-15-0.4488imageNBUD13;CPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;SF3B4;TARDBP;U2AF2;UPF1PXNMacrophages_M1GSVA_HALLMARK_MTORC1_SIGNALING
chr19:11834104-11835237:+
BLCAEERIRENSG00000177479.15chr348924715:48924839:48927461:48927725-0.33647.9003e-114.2613e-14-0.4038imageNBUD13;CPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;SF3B4;TARDBP;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:11834104-11835237:+
BLCAEERIRENSG00000101213.5chr2063534151:63534315:63534937:63535059-0.33959.3807e-111.8099e-15-0.4203imageNEIF4A3;FBL;TARDBP;U2AF2;UPF1NAT_cells_CD4_naiveGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000171295.11,ZNF440
BLCAEAGIRENSG00000131143.4chr1685804936:85805864:85806455:85806805-0.27811.9163e-083.5193e-15-0.4389imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000171295.11,ZNF440
BLCAEAGIRENSG00000102125.11chrX154418474:154419746:154420031:154420073-0.42061.1135e-133.5638e-17-0.4106imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000171295.11,ZNF440
BLCAEAGIRENSG00000186501.10chr127334150:27334754:27335378:27335648-0.28082.7748e-081.6866e-13-0.4210imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:11834104-11835237:+
BLCAEERIRENSG00000072518.16chr1163906087:63906114:63908259:63908304-0.33192.2840e-106.2600e-14-0.4013imageNBUD13;CPSF6;EIF4A3;ELAVL1;FBL;HNRNPA2B1;KHDRBS1;PRPF8;SF3B4;TARDBP;U2AF2;UPF1MARK2T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000171295.11,ZNF440
BLCAEAGESENSG00000093167.13chr337083644:37083806:37091466:37091538:37094791:370949080.32455.0592e-084.7253e-160.4017imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184LRRFIP2T_cells_regulatory_(Tregs)GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
ENSG00000171295.11,ZNF440
BLCAEAGIRENSG00000111615.8chr1275496903:75499951:75501722:755018160.32485.4887e-089.1295e-170.4038imageNADAR;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results



Top

5. Enriched editing regions and immune infiltration for ZNF440


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:11822622-11825135:+BLCAEERDendritic_cells_resting1.9958e-02-0.3622image
chr19:11834104-11835237:+BLCAEERMacrophages_M12.8941e-140.3723image
ENSG00000171295.11,ZNF440BLCAEAGMacrophages_M11.0469e-130.3642image
chr19:11834104-11835237:+BRCAEERT_cells_CD4_memory_resting1.9343e-040.1144image
ENSG00000171295.11,ZNF440BRCAEAGT_cells_CD4_memory_activated7.3987e-040.1035image
chr19:11834104-11835237:+CESCEERPlasma_cells2.4796e-02-0.1366image
ENSG00000171295.11,ZNF440CESCEAGPlasma_cells4.0621e-02-0.1247image
chr19:11834104-11835237:+CHOLEERT_cells_follicular_helper2.4398e-020.4580image
ENSG00000171295.11,ZNF440CHOLEAGT_cells_follicular_helper3.0009e-020.4434image
chr19:11834104-11835237:+COADEERNeutrophils1.6838e-050.2629image
ENSG00000171295.11,ZNF440COADEAGNeutrophils2.1322e-050.2589image
chr19:11834104-11835237:+DLBCEERT_cells_gamma_delta2.1052e-020.3780image
ENSG00000171295.11,ZNF440DLBCEAGB_cells_naive1.6016e-02-0.3833image
chr19:11814977-11819628:+ESCAEERT_cells_CD4_memory_activated8.1498e-030.2976image
chr19:11822622-11825135:+ESCAEERMacrophages_M23.6620e-020.2042image
chr19:11828388-11830024:+ESCAEERT_cells_gamma_delta2.8959e-020.2490image
chr19:11834104-11835237:+ESCAEERB_cells_naive1.3259e-03-0.2524image
ENSG00000171295.11,ZNF440ESCAEAGMacrophages_M03.6204e-030.2295image
chr19:11834104-11835237:+GBMEERB_cells_naive1.3146e-02-0.1945image
ENSG00000171295.11,ZNF440GBMEAGB_cells_naive1.3211e-02-0.1943image
chr19:11834104-11835237:+HNSCEERT_cells_regulatory_(Tregs)3.9067e-03-0.1359image
ENSG00000171295.11,ZNF440HNSCEAGT_cells_regulatory_(Tregs)3.8686e-03-0.1361image
chr19:11834104-11835237:+KIRCEERNK_cells_activated1.1102e-02-0.1337image
ENSG00000171295.11,ZNF440KIRCEAGNK_cells_resting4.9324e-02-0.1035image
ENSG00000171295.11,ZNF440KIRPEAGMacrophages_M14.9868e-020.1249image
chr19:11828388-11830024:+LAMLEERT_cells_regulatory_(Tregs)6.7500e-030.3982image
chr19:11834104-11835237:+LGGEERMonocytes4.0231e-040.1561image
ENSG00000171295.11,ZNF440LGGEAGMonocytes4.6339e-040.1545image
chr19:11834104-11835237:+LIHCEERMast_cells_resting1.8586e-020.1793image
ENSG00000171295.11,ZNF440LIHCEAGMast_cells_resting2.0296e-020.1748image
chr19:11834104-11835237:+LUADEEREosinophils8.5127e-040.1657image
ENSG00000171295.11,ZNF440LUADEAGEosinophils1.8143e-030.1543image
chr19:11834104-11835237:+LUSCEERMacrophages_M07.2893e-030.1254image
ENSG00000171295.11,ZNF440LUSCEAGMacrophages_M08.4649e-030.1230image
chr19:11814977-11819628:+OVEERT_cells_gamma_delta5.5406e-030.3539image
chr19:11822622-11825135:+OVEERMonocytes3.8742e-020.1898image
chr19:11834104-11835237:+OVEERMacrophages_M17.7949e-060.2605image
ENSG00000171295.11,ZNF440OVEAGMacrophages_M16.7040e-050.2331image
chr19:11834104-11835237:+PRADEERPlasma_cells9.8437e-05-0.1743image
ENSG00000171295.11,ZNF440PRADEAGPlasma_cells6.8729e-05-0.1779image
chr19:11834104-11835237:+READEERT_cells_gamma_delta2.1873e-020.2388image
ENSG00000171295.11,ZNF440READEAGT_cells_gamma_delta2.1995e-020.2386image
chr19:11834104-11835237:+SKCMEERNK_cells_resting3.1654e-02-0.1072image
ENSG00000171295.11,ZNF440SKCMEAGNK_cells_resting3.1342e-02-0.1074image
chr19:11814977-11819628:+STADEERMacrophages_M29.1137e-040.2735image
chr19:11828388-11830024:+STADEERMacrophages_M13.9042e-020.2047image
chr19:11834104-11835237:+STADEERT_cells_CD87.7936e-060.2381image
ENSG00000171295.11,ZNF440STADEAGT_cells_CD86.0596e-060.2402image
chr19:11834104-11835237:+TGCTEERMacrophages_M21.3571e-02-0.2152image
ENSG00000171295.11,ZNF440TGCTEAGMacrophages_M23.8074e-02-0.1807image
chr19:11834104-11835237:+THCAEERNK_cells_activated1.7615e-03-0.1448image
ENSG00000171295.11,ZNF440THCAEAGNK_cells_activated1.6281e-03-0.1459image
chr19:11834104-11835237:+THYMEERPlasma_cells1.0804e-020.2339image
ENSG00000171295.11,ZNF440THYMEAGMacrophages_M16.9572e-030.2472image
chr19:11834104-11835237:+UCECEERMacrophages_M17.9716e-030.2011image
ENSG00000171295.11,ZNF440UCECEAGMacrophages_M16.1422e-030.2058image


Top

6. Enriched editing regions and immune gene sets for ZNF440


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:11834104-11835237:+BLCAEER1.5099e-03image1.1966e-170.4148image
ENSG00000171295.11,ZNF440BLCAEAG1.1353e-03image7.5621e-170.4048image
chr19:11834104-11835237:+BRCAEER1.5923e-02image1.3994e-020.0755image
ENSG00000171295.11,ZNF440BRCAEAG2.6252e-02image2.6984e-030.0921image
chr19:11834104-11835237:+HNSCEER1.1327e-02image3.3902e-080.2568image
ENSG00000171295.11,ZNF440HNSCEAG9.7067e-03image3.3935e-080.2568image
chr19:11834104-11835237:+LUSCEER1.1462e-02image4.1392e-040.1645image
ENSG00000171295.11,ZNF440LUSCEAG1.2354e-02image6.0905e-040.1597image
chr19:11834104-11835237:+STADEER1.9674e-02image8.1878e-050.2104image
ENSG00000171295.11,ZNF440STADEAG1.5540e-02image6.0382e-040.1832image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000171295.11,ZNF440BLCAEAG9.0778e-100.30341.3010e-020.12556.9222e-100.30545.5488e-160.3941image
chr19:11834104-11835237:+BLCAEER6.4162e-120.33869.9116e-040.16613.6823e-120.34231.8394e-170.4126image
ENSG00000171295.11,ZNF440LGGEAG1.4931e-02-0.10772.0267e-04-0.16382.1703e-06-0.20801.7194e-030.1385image
chr19:11834104-11835237:+LGGEER1.4664e-02-0.10802.0435e-04-0.16372.5696e-06-0.20651.4275e-030.1408image
chr19:11822622-11825135:+STADEER3.0386e-030.21283.5287e-020.15202.5424e-020.16131.7837e-040.2673image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:11834104-11835237:+ACCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0511e-020.3519image
ENSG00000171295.11,ZNF440ACCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0511e-020.3519image
ENSG00000171295.11,ZNF440BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG8.7241e-230.4691image
chr19:11822622-11825135:+BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER6.8554e-030.4158image
chr19:11834104-11835237:+BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.1229e-240.4875image
chr19:11834104-11835237:+BRCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.5613e-060.1470image
ENSG00000171295.11,ZNF440BRCAGSVA_HALLMARK_COMPLEMENTEAG4.1356e-080.1675image
ENSG00000171295.11,ZNF440CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG5.7422e-030.1677image
chr19:11834104-11835237:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.2511e-030.1735image
chr19:11834104-11835237:+CHOLGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.6907e-02-0.4512image
ENSG00000171295.11,ZNF440CHOLGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.1029e-02-0.4409image
ENSG00000171295.11,ZNF440COADGSVA_HALLMARK_DNA_REPAIREAG2.8925e-05-0.2548image
chr19:11834104-11835237:+COADGSVA_HALLMARK_DNA_REPAIREER2.6383e-05-0.2570image
chr19:11834104-11835237:+DLBCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER9.3239e-030.4218image
chr19:11814977-11819628:+ESCAGSVA_HALLMARK_DNA_REPAIREER3.7224e-020.2364image
chr19:11828388-11830024:+ESCAGSVA_HALLMARK_UV_RESPONSE_UPEER3.3201e-030.3306image
chr19:11822622-11825135:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.4913e-030.2922image
ENSG00000171295.11,ZNF440ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG4.8074e-050.3165image
chr19:11834104-11835237:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER6.6514e-050.3109image
chr19:11834104-11835237:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5523e-040.2836image
ENSG00000171295.11,ZNF440GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6746e-040.2827image
ENSG00000171295.11,ZNF440HNSCGSVA_HALLMARK_COMPLEMENTEAG3.7460e-110.3055image
chr19:11834104-11835237:+HNSCGSVA_HALLMARK_COMPLEMENTEER3.0052e-110.3069image
chr19:11834104-11835237:+KICHGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER3.1173e-02-0.2697image
ENSG00000171295.11,ZNF440KICHGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG3.1173e-02-0.2697image
ENSG00000171295.11,ZNF440KIRCGSVA_HALLMARK_COMPLEMENTEAG2.3190e-030.1598image
chr19:11834104-11835237:+KIRCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER7.1911e-050.2077image
ENSG00000171295.11,ZNF440KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.1309e-040.2275image
chr19:11834104-11835237:+KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.2306e-050.2612image
chr19:11814977-11819628:+LAMLGSVA_HALLMARK_MITOTIC_SPINDLEEER9.9766e-03-0.3510image
chr19:11828388-11830024:+LAMLGSVA_HALLMARK_UV_RESPONSE_DNEER7.2221e-030.3952image
chr19:11822622-11825135:+LAMLGSVA_HALLMARK_P53_PATHWAYEER1.1292e-020.4293image
ENSG00000171295.11,ZNF440LGGGSVA_HALLMARK_MYC_TARGETS_V2EAG1.1226e-18-0.3771image
chr19:11834104-11835237:+LGGGSVA_HALLMARK_MYC_TARGETS_V2EER7.3755e-19-0.3789image
ENSG00000171295.11,ZNF440LIHCGSVA_HALLMARK_HEME_METABOLISMEAG1.1418e-030.2432image
chr19:11834104-11835237:+LIHCGSVA_HALLMARK_HEME_METABOLISMEER8.1757e-040.2529image
ENSG00000171295.11,ZNF440LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG4.0349e-050.2023image
chr19:11834104-11835237:+LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.6751e-050.2078image
ENSG00000171295.11,ZNF440LUSCGSVA_HALLMARK_HYPOXIAEAG3.2389e-070.2362image
chr19:11834104-11835237:+LUSCGSVA_HALLMARK_HYPOXIAEER2.4654e-070.2386image
chr19:11834104-11835237:+MESOGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.1434e-020.2759image
ENSG00000171295.11,ZNF440MESOGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.1434e-020.2759image
chr19:11834104-11835237:+OVGSVA_HALLMARK_APOPTOSISEER3.6123e-120.3952image
ENSG00000171295.11,ZNF440OVGSVA_HALLMARK_APOPTOSISEAG6.1599e-100.3548image
chr19:11822622-11825135:+OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.7535e-020.1909image
chr19:11814977-11819628:+OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.5086e-020.2891image
ENSG00000171295.11,ZNF440PAADGSVA_HALLMARK_ANGIOGENESISEAG5.1619e-040.2635image
chr19:11834104-11835237:+PAADGSVA_HALLMARK_ANGIOGENESISEER4.3973e-040.2667image
ENSG00000171295.11,ZNF440PCPGGSVA_HALLMARK_COAGULATIONEAG4.4575e-020.2281image
chr19:11834104-11835237:+PCPGGSVA_HALLMARK_COAGULATIONEER4.4575e-020.2281image
ENSG00000171295.11,ZNF440PRADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG7.5291e-050.1770image
chr19:11834104-11835237:+PRADGSVA_HALLMARK_UV_RESPONSE_DNEER4.8340e-050.1818image
chr19:11834104-11835237:+READGSVA_HALLMARK_UV_RESPONSE_DNEER3.7901e-050.4156image
ENSG00000171295.11,ZNF440READGSVA_HALLMARK_UV_RESPONSE_DNEAG6.6557e-050.4035image
chr19:11834104-11835237:+SARCGSVA_HALLMARK_MYOGENESISEER9.8810e-030.1781image
ENSG00000171295.11,ZNF440SARCGSVA_HALLMARK_MYOGENESISEAG1.0237e-020.1773image
chr19:11834104-11835237:+SKCMGSVA_HALLMARK_COAGULATIONEER4.1346e-060.2274image
ENSG00000171295.11,ZNF440SKCMGSVA_HALLMARK_COAGULATIONEAG4.0820e-060.2275image
ENSG00000171295.11,ZNF440STADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG5.5373e-050.2147image
chr19:11828388-11830024:+STADGSVA_HALLMARK_APICAL_SURFACEEER4.0447e-050.3947image
chr19:11834104-11835237:+STADGSVA_HALLMARK_MYOGENESISEER2.1803e-050.2264image
chr19:11822622-11825135:+STADGSVA_HALLMARK_GLYCOLYSISEER6.6331e-050.2838image
chr19:11814977-11819628:+STADGSVA_HALLMARK_UV_RESPONSE_UPEER6.4334e-030.2261image
ENSG00000171295.11,ZNF440TGCTGSVA_HALLMARK_SPERMATOGENESISEAG2.8633e-020.1906image
chr19:11834104-11835237:+TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER9.7500e-030.2251image
chr19:11834104-11835237:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER9.6418e-100.2790image
ENSG00000171295.11,ZNF440THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG9.4866e-100.2791image
chr19:11834104-11835237:+THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.5620e-040.3306image
ENSG00000171295.11,ZNF440THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.3722e-040.3245image
chr19:11834104-11835237:+UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.4661e-040.2641image
ENSG00000171295.11,ZNF440UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.5121e-050.2939image
ENSG00000171295.11,ZNF440UCSGSVA_HALLMARK_E2F_TARGETSEAG2.4320e-020.3120image
chr19:11834104-11835237:+UCSGSVA_HALLMARK_SPERMATOGENESISEER4.2517e-020.2824image
ENSG00000171295.11,ZNF440UVMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.6394e-02-0.2673image
chr19:11834104-11835237:+UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.6394e-02-0.2673image


Top

7. Enriched editing regions and drugs for ZNF440


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:11834104-11835237:+ACCFTI.277EER9.9758e-04-0.4433image
ENSG00000171295.11,ZNF440ACCFTI.277EAG9.9758e-04-0.4433image
ENSG00000171295.11,ZNF440BLCACGP.60474EAG7.3409e-18-0.4168image
chr19:11822622-11825135:+BLCAEHT.1864EER1.2291e-020.3876image
chr19:11834104-11835237:+BLCACGP.60474EER1.8575e-18-0.4241image
chr19:11834104-11835237:+BRCAAZD6482EER3.6838e-09-0.1802image
ENSG00000171295.11,ZNF440BRCAAZD6482EAG2.1234e-07-0.1587image
ENSG00000171295.11,ZNF440CESCAP.24534EAG2.8266e-02-0.1335image
chr19:11834104-11835237:+CESCAP.24534EER1.9573e-02-0.1420image
chr19:11834104-11835237:+CHOLBIBW2992EER1.8263e-02-0.4776image
ENSG00000171295.11,ZNF440CHOLBIBW2992EAG1.8620e-02-0.4763image
ENSG00000171295.11,ZNF440COADGW843682XEAG2.9084e-090.3557image
chr19:11834104-11835237:+COADGW843682XEER1.0045e-100.3864image
chr19:11834104-11835237:+DLBCABT.263EER1.2703e-02-0.4058image
ENSG00000171295.11,ZNF440DLBCImatinibEAG3.0531e-02-0.3468image
chr19:11814977-11819628:+ESCAJW.7.52.1EER4.6815e-02-0.2258image
chr19:11828388-11830024:+ESCABexaroteneEER9.7155e-03-0.2930image
chr19:11822622-11825135:+ESCAGNF.2EER5.8515e-04-0.3300image
ENSG00000171295.11,ZNF440ESCABexaroteneEAG1.6650e-05-0.3342image
chr19:11834104-11835237:+ESCABexaroteneEER5.6156e-06-0.3513image
chr19:11834104-11835237:+GBMBMS.754807EER4.2745e-050.3157image
ENSG00000171295.11,ZNF440GBMBMS.754807EAG4.7109e-050.3140image
ENSG00000171295.11,ZNF440HNSCEmbelinEAG3.5820e-10-0.2904image
chr19:11834104-11835237:+HNSCEmbelinEER3.5376e-10-0.2904image
chr19:11834104-11835237:+KICHATRAEER1.4865e-02-0.3032image
ENSG00000171295.11,ZNF440KICHATRAEAG1.4865e-02-0.3032image
ENSG00000171295.11,ZNF440KIRCDocetaxelEAG7.8437e-050.2063image
chr19:11834104-11835237:+KIRCCI.1040EER3.1373e-04-0.1889image
chr19:11834104-11835237:+KIRPCCT018159EER9.0158e-050.2465image
ENSG00000171295.11,ZNF440KIRPCCT018159EAG1.8742e-040.2355image
chr19:11822622-11825135:+LAMLLenalidomideEER3.1792e-020.3689image
chr19:11828388-11830024:+LAMLCCT018159EER4.4363e-040.5019image
chr19:11834104-11835237:+LAMLBryostatin.1EER4.6315e-02-0.2605image
chr19:11814977-11819628:+LAMLCGP.60474EER3.4037e-02-0.2917image
ENSG00000171295.11,ZNF440LAMLAICAREAG2.4193e-020.2336image
chr19:11834104-11835237:+LGGGSK.650394EER2.1195e-200.3941image
ENSG00000171295.11,ZNF440LGGGSK.650394EAG7.4846e-200.3888image
ENSG00000171295.11,ZNF440LIHCEtoposideEAG9.9382e-040.2461image
chr19:11834104-11835237:+LIHCEtoposideEER1.4452e-030.2411image
chr19:11834104-11835237:+LUADBMS.708163EER8.2790e-05-0.1950image
ENSG00000171295.11,ZNF440LUADAG.014699EAG1.0835e-04-0.1909image
ENSG00000171295.11,ZNF440LUSCAZ628EAG2.0802e-04-0.1727image
chr19:11834104-11835237:+LUSCAZ628EER1.4987e-04-0.1764image
chr19:11834104-11835237:+OVCI.1040EER1.4313e-04-0.2226image
chr19:11822622-11825135:+OVAICAREER5.5766e-040.3118image
chr19:11814977-11819628:+OVLenalidomideEER3.6905e-030.3693image
ENSG00000171295.11,ZNF440OVBMS.536924EAG2.1240e-04-0.2170image
ENSG00000171295.11,ZNF440PAADBX.795EAG7.1083e-05-0.2999image
chr19:11834104-11835237:+PAADBX.795EER6.1219e-05-0.3024image
chr19:11834104-11835237:+PCPGGDC.0449EER9.3069e-04-0.3676image
ENSG00000171295.11,ZNF440PCPGGDC.0449EAG9.3069e-04-0.3676image
chr19:11834104-11835237:+PRADCCT018159EER1.0773e-060.2174image
ENSG00000171295.11,ZNF440PRADCCT018159EAG1.3783e-060.2150image
chr19:11834104-11835237:+READAZD6482EER2.0764e-04-0.3775image
ENSG00000171295.11,ZNF440READAZD6482EAG4.5955e-04-0.3580image
chr19:11834104-11835237:+SARCBX.795EER2.0632e-03-0.2120image
ENSG00000171295.11,ZNF440SARCBX.795EAG2.0355e-03-0.2122image
chr19:11834104-11835237:+SKCMAZD7762EER9.4105e-07-0.2417image
ENSG00000171295.11,ZNF440SKCMAZD7762EAG9.2734e-07-0.2418image
ENSG00000171295.11,ZNF440STADBexaroteneEAG3.2649e-05-0.2210image
chr19:11834104-11835237:+STADBexaroteneEER1.3229e-05-0.2322image
chr19:11814977-11819628:+STADBMS.536924EER9.9372e-03-0.2142image
chr19:11822622-11825135:+STADCCT007093EER2.9934e-020.1567image
chr19:11828388-11830024:+STADGSK269962AEER7.2389e-04-0.3309image
chr19:11834104-11835237:+TGCTBMS.708163EER4.2924e-03-0.2480image
ENSG00000171295.11,ZNF440TGCTBMS.708163EAG2.1741e-02-0.1996image
ENSG00000171295.11,ZNF440THCAAZD.0530EAG1.2936e-05-0.2009image
chr19:11834104-11835237:+THCAAZD.0530EER1.7555e-05-0.1979image
chr19:11834104-11835237:+THYMDoxorubicinEER1.1613e-050.3916image
ENSG00000171295.11,ZNF440THYMDoxorubicinEAG3.4958e-070.4486image
chr19:11834104-11835237:+UCECJNJ.26854165EER9.7750e-04-0.2485image
ENSG00000171295.11,ZNF440UCECCI.1040EAG6.2517e-04-0.2554image
ENSG00000171295.11,ZNF440UCSJNK.Inhibitor.VIIIEAG1.0878e-02-0.3504image
chr19:11834104-11835237:+UCSCCT018159EER9.4430e-030.3567image
ENSG00000171295.11,ZNF440UVMEmbelinEAG1.1729e-030.4227image
chr19:11834104-11835237:+UVMEmbelinEER1.1729e-030.4227image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType